Skip to main content

Table 1 The demographic data on patients with PM/DM with ILD (excerptiona)

From: The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease

Variables

(n = 116 patients)

 

Values

 Women (n (%))

83/116 (71.6%)

 Age (years)

56.0 ± 14.8b

 Type (n)

PM 22, DM 51, CADM 43

Baseline data

CK (U/l)

360 (115–1496)c

LDH (U/l)

369 (279–526)c

KL-6 (U/ml)

673 (453–1030)c

CRP (mg/dl)

0.57 (0.15–1.78)c

Lymphocytes (/μl)

971 (696–1386)c

Albumin (g/dl)

3.42 ± 0.56b

PaCO2 (mmHg)

37.3 (34.3–40.3)c

Ferritin (ng/ml)

360 (165–843)c

Autoantibody (n (%))

Anti-Jo-1 Ab

21/114 (18.4%)

Anti-ARS Ab

9/45 (20.0%)

Anti-MDA5 Ab

8/31 (25.8%)

Anti-TIF-1γ Ab

2/2 (100%)

Malignancy (<3 years) (n (%))

21/112 (18.8%)

Treatment (n (%))

Initial PSL dose (mg/kg/day)

0.83 ± 0.29b

mPSL pulse

77/116 (66.4%)

IVCY

48/116 (41.4%)

Calcineurin inhibitor

81/115 (70.4%)

Combination therapyd

40/116 (34.5%)

Prognosis (n (%))

Death

28/116 (24.1%)

Serious infection

38/116 (32.8%)

  1. CK creatine kinase, LDH lactate dehyrdrogenase, CRP C-reactive protein, PaCO 2 arterial partial pressure of carbon dioxide, PSL prednisolone, mPSL intravenous methyl-prednisolone, IVCY intravenous cyclophosphamide, PM polymyositis, DM dermatomyositis, CADM clinically amyopathic dermatomyositis
  2. aSee also Additional file 1: Table S1
  3. bThe data are shown as the mean ± standard deviation
  4. cValues are the median (interquartile range)
  5. dCombination therapy includes glucocorticoid, IVCY and calcineurin inhibitors
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us